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Abstract 
Introduction: Recent data suggest that statin use after intracerebral hemorrhage (ICH) might 
be beneficial. However, data on the effects of early in-hospital statin exposure are lacking. 
Therefore, we sought to assess whether 1) early statin exposure during the acute phase after 
ICH and 2) early continuation of prevalent statin use are associated with favorable functional 
outcome. 
Patients and methods: Data were obtained from the Virtual International Stroke Trials 
Archive. Patients were categorized according to use patterns of statins during this early in-
hospital phase (continuation, discontinuation or new initiation of statins). Univariate and 
multivariable analyses were conducted to explore the association between early statin 
exposure and functional outcome. 
Results: A total of 919 patients were included in the analysis. Early in-hospital statin exposure 
(n=89, 9.7%) was associated with better functional outcome (modified Rankin Scale ≤3) 
compared with 790 patients without statin exposure before or early after the event (66% vs 
47%, adjusted OR [adjOR] 2.1, 95% confidence interval [95%CI] 1.3–3.6).  
Compared with patients without exposure to statins before and early after the event, early 
continuation of statin therapy (n=57) was associated with favorable functional outcome (adjOR 
2.6, 95%CI 1.3-5.2). The association between early continuation of statins and outcome 
remained robust in sensitivity analyses restricted to patients able to take oral medication 
within 72 hours and one-week survivors.  
Conclusion: Statin exposure and continuation of prevalent statin therapy early after ICH are 
associated with favorable functional outcome after 90 days. It is, however, possible that our 
results are not due to a protective effect of statins after ICH but are confounded by indication 
bias. 
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Introduction 
Treatment with HMG-CoA-reductase-inhibitors (statins) in patients with acute ischemic stroke 
is associated with improved survival and better functional outcome.1, 2 However, in 
intracerebral hemorrhage (ICH), which constitutes 10-15% of all strokes,3 use of statins is 
considered more controversial.4, 5  
Treatment with statins in patients with recent stroke might be associated with a modestly 
increased risk for future ICH.4, 6, 7 On the other hand, there is evidence from observational and 
animal studies that exposure to statins at any time during hospitalization for ICH is associated 
with better outcomes and reduced mortality, while discontinuation of statins after ICH is 
associated with higher rates of poor clinical outcome and mortality.8-12 However, previous 
studies did not provide data regarding timing of statin use, specifically continuation of statin 
during the first few days after ICH.8-10 This early in-hospital phase is relevant because of 
potential early rebound effects associated with statin discontinuation.13-16 Animal model studies 
in mice with cerebral ischemia, showed loss of protective statin effects as early as two days 
after their discontinuation.17  
Altogether, uncertainty remains on how to proceed with pre-existing statin therapy, especially 
in the early in-hospital phase after ICH. This is mirrored by the current guidelines from the 
American Heart Association and American Stroke Association on the management of 
spontaneous ICH, which have no clarity on statin use in patients with recent ICH.18 There are, 
however, expert recommendations outside of guidelines suggesting that prevalent statin use 
should be continued during the early in-hospital phase.19-21 
Using the Virtual International Stroke Trials Archive (VISTA) database we sought to study 
whether exposure to statins during the early in-hospital phase, and especially whether 
continuation of prevalent statin use is associated with a better functional outcome at 90 days. 
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Methods 
Data source, and patients 
Data were obtained from the Virtual International Stroke Trials Archive - ICH database 
(VISTA-ICH, URL: http://www.virtualtrialsarchives.org/vista/). The VISTA database collects 
data from a variety of clinical trials for exploratory analyses; its design and goals have been 
published previously.22 Prior to the data analysis, a project proposal with definitions of our 
outcome parameters was approved by the independent VISTA steering committee. 
 
We included all patients with primary ICH and having available data on age, prior and 
concurrent medication, clinical severity as measured by Glasgow Coma Scale (GCS), 
hematoma volume, systolic blood pressure at baseline and functional outcome after 90 days. 
Figure 1 shows patient inclusion into our analysis as well as distribution of patients according 
to statin therapy. Functional outcome was measured using the modified Rankin Scale (mRS). 
Patients on oral anticoagulation before the event were excluded from the study, as there are 
differences in clinical outcome in these patients.23 
 
Figure 1. Data collection and group allocation 
[Insert Figure 1.] 
mRS, modified Rankin Scale; ICH, Intracerebral hemorrhage; GCS, Glasgow Coma 
Scale 
 
 
Definition of early statin use 
We categorized patients into four groups according to early in-hospital statin exposure in the 
first 48 hours after the event: 1) patients without statin exposure before and early after the event 
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(‘no statin use’), 2) patients who continued prevalent statin treatment within 48 hours and 
continued this therapy at least until day 7 after the event (‘early continuation’), 3) patients who 
discontinued statin use after ICH in the first 48 hours after ICH (‘early discontinuation’), and 
4) patients newly started on statins within 48 hours after the event and continued this therapy 
at least until day 7 after the event (‘new early initiation’; see figure 2). Early in-hospital statin 
exposure was defined as documented treatment with statins within the first 48 hours after 
admission irrespective of prevalent statin therapy before ICH (combination of groups 2 and 4).  
Group 1 included patients with late initiation of statins after 48 hours but within the first week 
after ICH, and group 3 included patients with late continuation after 48 hours but within the 
first week after the event.  
 
Figure 2. Patient groups according to statin exposure 
[Insert Figure 2.] 
 ICH, Intracerebral hemorrhage 
 
Study outcomes 
Outcome of interest was favorable functional outcome after 90 days, defined as mRS ≤ 3. This 
outcome measure was chosen to facilitate comparability with other studies on ICH.9, 24 Further 
outcomes were distribution of 90-day mRS and mortality at 90 days. 
 
Statistical analysis 
For univariate analysis Pearson’s chi-squared test, Mann-Whitney-U-test and student’s T-test 
were used where appropriate. Unadjusted and adjusted multiple logistic regression analyses 
were conducted to explore the association between statin exposure and favorable functional 
outcome. Statin use was entered as a 4-group categorical variable. Patients without statin 
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exposure before and early after ICH (‘no statin use’) were used as reference. In order to explore 
the association of early statin therapy after ICH and favorable shift in 90-day mRS, we 
conducted an ordinal logistic regression analysis. The models were adjusted for age, sex, 
hematoma volume, history of prior antithrombotic use, Glasgow Coma Scale (GCS) and 
systolic blood pressure on admission. These variables are established risk factors for 
unfavorable outcome after ICH and could be linked to clinical decisions regarding statin 
treatment (re) initiation.25-28 The variables had to be available for at least 90% of the cohort and 
were checked for relevant multicollinearity within the model, which was defined as the largest 
condition index ≥ 30.29  
We also compared the association between early continued statin exposure (‘early 
continuation’) and favorable outcome with patients who discontinued statins (‘early 
discontinuation’). Due to limited numbers, the multiple logistic regression analysis only 
included age and hematoma volume. Furthermore, we compared functional outcomes of 
patients who continued statin therapy early after ICH (‘early continuation’) with those who 
continued statins later (i.e. between days 3 and 7 after ICH, ‘late continuation’).  
In addition, we performed two sensitivity analyses, restricting our multiple logistic regression 
to patients with documented intake of oral medication in the first 72 hours in order to try to rule 
out patients unable to take statins because of dysphagia and to one-week survivors in an attempt 
to reduce selection bias. In two further sensitivity analyses we 1) replaced GCS with NIHSS 
into our original model and 2) added intraventricular hemorrhage into our original model. 
Two-sided p-values < 0.05 were considered statistically significant. All data were analyzed 
using SPSS version 25 (IBM, Chicago, USA).  
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Results 
Of 987 ICH patients recorded in VISTA-ICH, 919 fulfilled inclusion criteria. Thirty-five 
patients were excluded because of missing data on either mRS at 90 days (19 patients), 
information on early statin exposure (1 patient), baseline GCS and/or hematoma volume (12 
patients) and/or systolic blood pressure (3 patients). Another 33 patients were excluded because 
they were on oral anticoagulant treatment at the time of the event (figure 1). 
Of these 919 patients, mean age was 65.6 ± 12.4 years, 66% were male, median baseline GCS 
was 15 (interquartile range [IQR] 13-15), median baseline NIHSS was 13 (IQR 9-18) median 
ICH volume was 15 ml (IQR 7-30 ml) and median onset to randomization time was 3.5 hours 
min (IQR 2.75 – 4.65).  
 
Statin exposure 
Prevalent statin use upon hospital admission was present in 97 patients (10.6%). Of these, 57 
patients (6.2%) continued statin treatment within 48 hours after ICH, while 40 patients (4.4%) 
discontinued statin use in the first 48 hours after the event. The latter included 7 patients (0.8%) 
who continued statins later than 48 hours but within the first week after ICH. New early statin 
exposure (i.e. new initiation of treatment within 48 hours) was observed in 32 patients (3.5%), 
while 790 (86.0%) patients were not on statins before and early after the event. The latter 
included 49 patients (5.3%) with late initiation of statin therapy later than 48 hours but within 
the first week. Any early in-hospital statin exposure was documented in 89 patients (9.7%). 
Table 1 shows baseline characteristics according to early in-hospital statin exposure.  
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Table 1.  Baseline characteristics according to early in-hospital statin use 
 No statin use 
n=790 
Early continuation 
of statins 
n=57 
Early 
discontinuation of 
statins 
n=40 
New early 
initiation of statins 
n=32 
Age, years, mean 
(Std. derivation) 
65.2 (±12.6) 67.2 (±8.9)  69.8 (±12.0) 67.0 (±10.6) 
Male sex, % (n) 64.3 (509) 63.2 (36) 60.0 (24) 53.1 (17) 
GCS base, 
median (IQR) 
15 (13-15) 15 (14-15) 14 (12-15) 15 (12-15) 
NIHSS base, 
Median (IQR) 
14 (9-18) 11 (7-15) 14 (11.5-19.5) 11 (7-18.5) 
Hematoma 
volume, ml, 
median (IQR) 
15.7 (8-30.8) 9.5 (4.9-19.3) 20.4 (8.6-44.1) 10.8 (3.4-22.4) 
Systolic Blood 
pressure base, 
mmHg, median 
(IQR) 
175 (156-195) 160 (144-182) 165 (151- 187) 178 (162 – 200) 
History of 
Diabetes mellitus, 
% (n) 
13.9 (110) 45.6 (26) 35.0 (14) 28.1 (9) 
History of 
hypertension, % 
(n) 
80.1 (633) 94.7 (54) 77.5 (31) 93.8 (30) 
Prior use of 
antithrombotics, 
%, n 
12.5 (99) 
 
43.9 (25) 52.5 (21) 0 (0) 
Std. derivation, Standard derivation; IQR, Interquartile Range; NIHSS, National Institute of Health Stroke 
Scale; GCS, Glasgow Coma Scale 
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Compared with patients not on statins before and early after the event, patients with continued 
statin use had lower hematoma volume (median 9.5 ml vs. 15.7 ml, p=0.002), lower systolic 
blood pressure at admission (median 160 mmHg vs. 175 mmHg, p = 0.003), and were more 
often on antithrombotic drugs before the event (43.9% vs. 12.5%, p <0.001).  
 
Functional outcome at 90 days 
Median mRS at day 90 was 4 (IQR 2-5), and frequency of unfavorable outcome (mRS 4-6) was 
50.9% (n=468). Frequency of favorable outcome according to early in-hospital statin exposure 
is shown in table 2. Early in-hospital statin exposure (‘early continuation’ and ‘new early 
initiation’) was associated with better functional outcome at 90 days compared with no early 
statin exposure (66.3% vs 47.2%, unadjusted Odds Ratio [OR]  2.20, 95% Confidence Interval 
[95% CI] 1.39 – 3.48). These results were confirmed after adjusting for age, sex, hematoma 
volume, prior use of antithrombotics and GCS and systolic blood pressure at initial presentation 
(adjusted OR 2.13, 95% CI 1.26 – 3.60). 
When statin exposure was entered as a categorical variable into the model with patients without 
statin use (‘no statin use’) as reference, early continuation of preexisting statin therapy was 
associated with higher probability of favorable functional outcome (unadjusted OR 2.78, 95% 
CI 1.53-5.04). After adjustment for age, sex, hematoma volume, prior use of antithrombotics 
and GCS and systolic blood pressure at initial presentation, early continuation of statins 
remained significantly associated with favorable functional outcome (adjusted OR 2.64, 95% 
CI 1.34-5.20), while early discontinuation of statins (adjusted OR 0.75, 95%CI 0.34-1.66) and 
new early initiation of statins (adjusted OR 1.44, 95% CI 0.64-3.27) were not (table 2). To 
account for bias conveyed by lower clinical severity in patients with early statin continuation 
we replaced GCS by NIHSS into our original model, and, second, included presence of 
intraventricular hemorrhage at baseline (n=265) into our original model. The results regarding 
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the association between early statin continuation and favorable outcome remained robust 
(adjusted OR 2.37, 95% CI 1.19 – 4.72 and adjusted OR 2.41, 95% CI 1.20 – 4.88, respectively). 
 
Using ordinal regression analysis there also was an association between early statin 
continuation and a shift towards a favorable mRS score (adjusted common OR for early statin 
continuation 2.13, 95% CI 1.30-3.51; table 2 and figure 3). 
 
Table 2. Association between early in-hospital statin use after ICH and functional outcome 
 Favorable outcome (mRS 0-3 at 90 days) Favorable distribution of mRS 
 Logistic Regression Ordinal Regression 
Statin use n/N (%) Unadjusted OR Adjusted OR* Unadjusted OR Adjusted OR* 
No statin use 379/790 
(48.0) 
1 (reference) 1 (reference) 1 (reference) 1 (reference) 
Early 
continuation of 
statins 
41/57 (71.9) 2.78 (1.53-5.04) 2.64 (1.34-5.20) 2.35 (1.47-3.75) 2.13 (1.3-3.51) 
Early 
discontinuation 
of statins 
13/40 (32.5) 0.52 (0.27 – 1.03) 0.75 (0.34-1.66) 0.63 (0.37-1.08) 1.00 (0.56 – 1.78) 
New early 
initiation of 
statins 
18/32 (56.3) 1.39 (0.68-2.84) 1.44 (0.64-3.27) 1.49 (0.81-2.76) 1.78 (0.93 – 3.42) 
mRS, modified Ranking Scale; OR, Odds Ratio 
*adjusted for age, sex, hematoma volume, prior use of antithrombotics and Glasgow Coma Scale and 
systolic blood pressure at initial presentation 
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Figure 3. Distribution of mRS at 90 days according to statin exposure 
[Insert Figure 3.] 
 mRS, modified Ranking Scale; OR, Odds Ratio; 95% CI, 95% Confidence Interval 
When directly compared with early discontinuation of statin therapy, early continuation of 
preexisting statin therapy was also associated with higher probability of favorable functional 
outcome (72 % vs 33%, p < 0.001, unadjusted OR 5.32, 95% CI 2.21-12.21, adjusted OR 3.87, 
95% CI 1.46 – 10.27, adjusted for age and hematoma volume). Similarly, early statin 
continuation was associated with a shift towards favorable mRS score (adjusted common OR 
for continued statin use 2.75, 95% CI 1.24 – 6.08; versus early discontinuation of statins).  
 
Finally, we compared early and late continuation of statins (n=57 and n=7). Frequency of 
favorable outcome was higher in the early continuation group (71.9% vs 42.9%, p = 0.117, 
unadjusted OR 3.4, 95% CI 0.7 – 17.0). Because of the small number of patients with late 
continuation of statin therapy, we did not perform a multiple logistic regression analysis.  
 
Mortality at 90 days 
Within the first 90 days after ICH, 183 patients (19.9%) died. Patients with early in-hospital 
statin exposure (‘early continuation’ and ‘new early initiation’) were less likely to die within 
90 days than patients without statin exposure (9% vs. 21%, p=0.007, unadjusted OR 0.37, 95% 
CI 0.18 – 0.8, adjusted OR 0.4, 95% CI 0.2 – 0.97).  
90-day mortality was non-significantly lower in the early continuation group, when compared 
with the ‘no statin’ group (21% versus 11%, p=0.074, unadjusted OR 0.4, 95% CI 0.2 – 1.1, 
adjusted OR 0.6, 95% CI 0.2 – 1.5, table 3), and when compared with the early discontinuation 
group (11% versus 23%, p=0.108, unadjusted OR 0.4, 95% CI 0.1 – 1.3, adjusted OR 0.7, 95% 
CI 0.2 – 2.5). 
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Table 3. Association between early in-hospital statin use after ICH and mortality at 90 days 
 Death until day 
90 
  
Statin use n/N (%) Unadjusted OR Adjusted OR* 
No statin use 166/790 (21.0) 1 (reference) 1 (reference) 
Early continuation 
of statins 
6/57 (10.5) 0.4 (0.12 – 1.1) 0.6 (0.2 -1.5) 
Early 
discontinuation of 
statins 
9/40 (22.5) 1.1 (0.5 – 2.3) 0.7 (0.3 – 1.8) 
New early initiation 
of statins 
2/32 (6.3) 0.3 (0.1-1.1) 0.2 (0.1 – 1.0) 
OR, Odds Ratio 
*adjusted for age, sex, hematoma volume, prior use of antithrombotics and Glasgow Coma Scale and 
systolic blood pressure at initial presentation 
 
Sensitivity analysis regarding functional outcome 
In an attempt to reduce selection bias generated by patients unable to take statins because of 
dysphagia, we performed a sensitivity analysis regarding favorable 90-day outcome. First, we 
excluded 313 patients for whom no intake of any oral medication within the first 72 hours was 
documented. Our results stayed robust (frequency of favorable outcome in patients with early 
continuation of statins compared with no statin exposure (75% vs 53%, unadjusted OR 2.65, 
95% CI 1.27 – 5.54; adjusted OR 2.92, 95% CI 1.26 – 6.75). Similarly, another sensitivity 
analysis restricted to 839 patients who survived the first week after ICH, showed similar 
associations in the multiple logistic regression analysis (frequency of favorable outcome in 
patients with early continuation of statins compared with no statin exposure 73% vs 53%, 
unadjusted OR 2.40, 95% CI 1.31 – 4.42; adjusted OR 2.55, 95% CI 1.28 – 5.09).  
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Discussion 
In this study, early in-hospital exposure to statins after acute ICH was associated with better 
functional outcome compared with no statin exposure early after the event. Our data suggests 
that this association is particularly driven by continuation of  pre-existing statin use within the 
first two days after the event. Thus, our findings provide clinical evidence to support current 
expert recommendations that prevalent statin use should be continued during the early in-
hospital phase.19-21 
Several hospital-based observational studies have explored the association between in-hospital 
statin exposure and functional outcome after ICH:8, 9, 30 In a study of 3218 Chinese patients with 
ICH, in-hospital statin use (at any time during hospitalization) was associated with a better 
functional outcome at 3 months and 1 year, in comparison to patients without in-hospital statin 
use.30 Data from other studies show more conflicting results.8, 9 In an analysis of data from the 
Ethnic/Racial Variations of Intracerebral Hemorrhage (ERICH) study, a prospective hospital-
based multicenter study of 2457 patients with ICH, there was a signal towards better functional 
outcomes among patients with in-hospital statin use (combined group of patients with continued 
statin use and new statin use) compared with discontinuation of statins. This was, however, no 
longer statistically significant when a propensity score accounting for variables that could have 
influenced the decision to treat with statins was included in the analysis.8 Similarly, an analysis 
of data from 2466 patients from the registry of the Canadian stroke network found an 
association between in-hospital statin discontinuation (at any time) and poor functional short-
term outcome which became borderline statistically significant after excluding patients treated 
palliatively.7  
Importantly, these studies did not define the timing of in-hospital statin exposure. We 
hypothesize that any protective or detrimental effects of statins would occur early following 
index ICH. Clinically, the early phase after ICH is critical because of the risk for hematoma 
expansion, development of perihematomal edema and re-bleeding.31-34 Hence, continuation of 
15 
 
statin therapy early after ICH is reasonable to avoid rebound effects associated with statin 
discontinuation.13-15 This argument is supported by animal models, where the protective effect 
of statins was lost within 2 days after their withdrawal.17 Moreover, clinical data show, that 
withdrawing statin therapy within the first 24 hours after myocardial infarction is associated 
with increased in-hospital mortality, compared to patients without statin use.35 These findings 
might explain that our observed associations remained stable even after adjusting for strong 
predictors of outcome after ICH.  
It should be mentioned, that a direct comparison between early and late continuation of statins 
also is of high interest, when assessing the necessity to continue statin therapy early after ICH. 
However, late continuation of statins was rare in our cohort limiting the statistical power to 
detect statistically significant differences. 
 
In our study, statin exposure early after ICH was significantly associated with a reduced odds 
of 90-day mortality compared with patients without statin exposure. Likewise, there was a 
signal towards lower mortality in patients who continued statins within 48 hours after ICH, 
though this was not statistically significant. This is in line with most data derived from 
observational studies focusing on mortality as outcome parameter. In a recent meta-analysis by 
Lei and colleagues comprising seven studies, in hospital-statin exposure was associated with 
an approximately 60% reduced odds of mortality.36 Interestingly, our observed associations fit 
well within these results and extend these observations to the early in-hospital phase. 
 
Strengths and limitations 
The strength of our study is the large sample size of the VISTA ICH database which is based 
on multicenter randomized controlled trials on (hyper-)acute ICH. The high data quality 
required in clinical trials with rigorous documentation of time points of drug administration 
allowed us to define and measure early in-hospital statin use.  
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There are limitations to this analysis. First, our results could be confounded by indication bias. 
Patients with presumed good prognosis at index ICH might have received statins more likely 
compared to those with presumed poor prognosis. This also falls into weight as our database 
lacked information on the exact reason to start or continue statin treatment, such as prevalence 
of coronary disease, severe carotid artery disease or history of ischemic stroke. Reassuringly, 
results from the sensitivity analysis, limited to one-week survivors, remained statistically 
significant with similar effect measures being detected. Moreover, as our database consists of 
patients that participated in randomized controlled trials (RCTs), confounding by indication 
bias could be lower than in registry studies. Patients enrolled in RCTs usually differ from those 
registered in hospital-based cohorts in particular with regard of co-morbidities and prognosis 
as patients with a presumably bad prognosis are often not included in RCTs. This presumption 
is corroborated by the high median GCS in our patient population suggesting an overall mild-
to-moderate ICH severity.  Thus, our findings may not apply to a more severely affected ICH 
population.  
Second, statins cannot be administered intravenously. Therefore patients with dysphagia, which 
is a common complication of stroke, are unable to take statins.37 To account for this, we 
performed yet another sensitivity analysis, excluding patients for whom no intake of oral 
medication was documented in the first 72 hours. Again, our results stayed robust in this 
analysis. However, it has to be noted, that the reason for not administering oral medication was 
not documented in our database. It is therefore possible, that there were other reasons to 
withhold oral medication (and therefore statins) than dysphagia.  
Third, the number of patients on statins was small, especially in the continuation and 
discontinuation groups. Therefore, we were not able to study potential effects of statin type or 
statin dose. This could be important as there is an association between higher dose of statin use 
and risk of symptomatic ICH after intravenous thrombolysis for ischemic stroke.38 Moreover, 
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sample size did not allow us to provide reasonable comparison of early versus late continuation, 
as well as early versus late new treatment initiation.  
Fourth, we have no data on the exact location of ICH, presence and location of cerebral 
microbleeds, hematoma expansion, and recurrent ICH. This could be of significance as all these 
factors are associated with outcome and potentially affected by statin exposure.39-43 Finally, our 
data lacked information on cholesterol levels of our patients. Therefore, we were unable to 
interpret the association between outcome and cholesterol levels.44 
 
Conclusion 
We observed an association between continued statin use during the early in-hospital phase 
after ICH (<48 hours) and a favorable functional outcome at 90 days. We are unable to 
differentiate if this association was due to a protective effect of early statin use in ICH patients 
or whether the use of statins was a surrogate parameter for an expected better prognosis. Still, 
our results provide clinical evidence supporting current expert recommendations to continue 
statins early after ICH. Well-designed randomized controlled-trials are warranted to further 
answer questions about statin continuation in the setting of acute ICH. 
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